Genervon Announces Biomarker Data From GALS-001 Clinical Trial For ALS
6/30/2014 10:53:40 AM
PASADENA, Calif.--(BUSINESS WIRE)--Genervon Biopharmaceuticals LLC (“Genervon”) today announced that it has analyzed and generated a Biomarker Data Report for its recent Phase 2a clinical trial for ALS disease modification. A full analysis of the trial’s results is expected to be completed in the third quarter of 2014, but preliminary clinical data and this biomarker data suggest that GM604—Genervon’s novel, proprietary, multi-target biological drug candidate—shows significant promise for treating ALS.
Help employers find you! Check out all the jobs and post your resume.
comments powered by